

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/763,329	07/09/2001	Joachim Messing	13259-00011	4832
75	90 11/05/2003		EXAM	INER
JANET E. REED, ESQUIRE			MEHTA, ASHWIN D	
	WASHBURN LLP		APTIBUT	DADED MINORD
ONE LIBERTY PLACE		ART UNIT	PAPER NUMBER	
46TH FLOOR			1638	
PHILADELPHI	A. PA 19103			

DATE MAILED: 11/05/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)
Office Action Summary		09/763,329	MESSING ET AL.
		Examin r	Art Unit
		Ashwin Mehta	1638
P riod fo	The MAILING DATE f this communication approximation of Reply	ppears on the c ver sheet w	ith the correspondence address
THE - Exte after - If the - If NC - Failu - Any	MAILING DATE OF THIS COMMUNICATION ensions of time may be available under the provisions of 37 CFR 12 SIX (6) MONTHS from the mailing date of this communication. Experiod for reply specified above is less than thirty (30) days, a reduce of the provision of the maximum statutory period for reply within the set or extended period for reply will, by stature ply received by the Office later than three months after the mailing datent term adjustment. See 37 CFR 1.704(b).	I. 1.136(a). In no event, however, may a reply within the statutory minimum of third will apply and will expire SIX (6) MONute, cause the application to become AE	reply be timely filed ty (30) days will be considered timely. ITHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).
1)🛛	Responsive to communication(s) filed on 15	5 July 2003 .	
2a)⊠	This action is FINAL . 2b) 7	This action is non-final.	
3)□ Disposit	Since this application is in condition for allow closed in accordance with the practice under ion of Claims	•	·
4)⊠	Claim(s) <u>11,13,14,16,17 and 22-30</u> is/are pe	ending in the application.	
	4a) Of the above claim(s) is/are withdr	awn from consideration.	
5)	Claim(s) is/are allowed.		
6)⊠	Claim(s) 11,13,14,16,17,22-27,29 and 30 is/a	are rejected.	
7)⊠	Claim(s) 28 is/are objected to.		
8)□	Claim(s) are subject to restriction and	or election requirement.	
Applicati	ion Papers		
9)	The specification is objected to by the Examin	er.	
10)🖾	The drawing(s) filed on <u>15 July 2003</u> is/are: a)⊠ accepted or b)☐ objected	to by the Examiner.
	Applicant may not request that any objection to t	- '	, <i>,</i>
11) 🔲	The proposed drawing correction filed on	is: a)□ approved b)□ d	isapproved by the Examiner.
	If approved, corrected drawings are required in r	•	
12) 🔲 .	The oath or declaration is objected to by the E	xaminer.	
Priority ι	under 35 U.S.C. §§ 119 and 120		
13)	Acknowledgment is made of a claim for foreign	gn priority under 35 U.S.C. §	§ 119(a)-(d) or (f).
a)[☐ All b)☐ Some * c)☐ None of:		
	1. Certified copies of the priority documer	nts have been received.	
	2. Certified copies of the priority documer	nts have been received in A	pplication No
* 5	3. Copies of the certified copies of the pri- application from the International B See the attached detailed Office action for a lis	Sureau (PCT Rule 17.2(a)).	·
	Acknowledgment is made of a claim for domes		
) The translation of the foreign language property in the control of the contro		
	Acknowledgment is made of a claim for domes	• •	
Attachmen	t(s)		
2) 🔲 Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)		Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152)

DETAILED ACTION

- 1. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- 2. The amendment to the first page of the specification, inserting a sentence to claim priority to earlier applications, has been entered.
- 3. The objection to the specification is withdrawn.
- 4. The rejection of claims 1 and 5-7 under 35 U.S.C. 101 is withdrawn, in light of the claim cancellations.
- 5. The rejection of claims 1-18 under 35 U.S.C. 112, 2nd paragraph, is withdrawn in light of the claim cancellations and amendments.
- 6. The rejection of claim 16 under 35 U.S.C. 112, 1st paragraph, is withdrawn in light of Applicants' arguments in the paper submitted July 15, 2003.
- 7. The rejection of claims 1, 2, 5, 8-10, and 12 under 35 U.S.C. 102(e) is withdrawn, in light of their cancellation.

Art Unit: 1638

Claim Objections

8. Claim 28 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Claim Rejections - 35 USC § 112

9. Claims 11, 13, 14, 17 remain and new claims 22-27, 29, and 30 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention, for the reasons of record stated in the Office action mailed January 16, 2003 under item 7. Applicants traverse in the paper submitted July 15, 2003. Applicants' arguments have been fully considered but were not found persuasive.

Applicants argue that the amended and new claims are directed to subject matter that is adequately described by the specification (response, page 12, 1st full paragraph). However, the amended and new claims are broader in scope than the originally examined claims, in that the chimeric gene can now comprise the coding region of any 10 kDa zein, from any source. As discussed previously, the specification only describes the coding region of the maize 10 kDa delta zein.

Application/Control Number: 09/763,329

Art Unit: 1638

10. Claims 11, 13, 14, and 17 remain and new claims 22-27, and 29 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention, for the reasons of record stated in the Office action mailed January 16, 2003 under item 8. Applicants traverse in the paper submitted July 15, 2003. Applicants' arguments have been fully considered but were not found persuasive.

Applicants argue that the amended and new claims are directed to subject matter that is adequately enabled by the specification (response, page 12, 1st full paragraph). However, as discussed above, the chimeric gene of the claims can now encompass any 10 kDa zein coding region. However, the specification only enables the claimed invention when the coding region is from the maize 10 kDa delta zein gene. The specification also does not teach that methionine content of corn seeds can be increased by transgenically expressing other types of 10 kDa zeins.

Claims 11, 13, 14, 16, 17, and 22-24 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims are broadly drawn towards a method of making high methionine corn seeds that produce saturation levels of any 10 kDa zein regardless of the dzr1 allelic composition of the seed, comprising transforming corn plant cells with a vector comprising a chimeric gene

Application/Control Number: 09/763,329

Art Unit: 1638

encoding any 10 kDa zein, operably linked to any promoter at its 5' end and to a heterologous 3' UTR at its 3' end, regenerating a fertile transformed plant, and producing seeds from the plant, wherein the seeds express the chimeric gene and produce saturation levels of the 10 kDa zein; a fertile transgenic corn plant produced by said method.

The specification teaches the construction of a plant transformation vector, pJM2710, in which the coding sequence of the maize 10 kDa delta zein is operably linked to the 27 kDa zein gene promoter and the CaMV 35S 3' polyA sequence. Transgenic maize plants comprising the vector were produced. The transgenic plants exhibited a higher level of expression of the 10 kDa delta zein as compared to non-transgenic Mo17. Progeny of crosses between the transgenic plant and Mo17 expressed high levels of the 10 kDa delta zein regardless of the direction of the cross (pages 24-29, Examples 1-5).

However, the specification does not describe a method of making high methionine seeds that produce saturation levels of 10 kDa zein. There is no written description support in the specification for producing "saturation levels" of any 10 kDa zein. This is a **NEW MATTER** rejection.

Claim Rejections - 35 USC § 103

12. Claim 11 remains and claims 17, 22-25, 29, and 30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bagga et al. (U.S. Patent No. 5,990,384) in combination with Hirt et al. (Curr. Genet., 1990, Vol. 17, pages 473-479) and Gordon-Kamm et al. (Plant Cell, 1990, Vol. 2, pages 603-618), for the reasons of record stated in the Office action mailed January 16, 2003

Application/Control Number: 09/763,329

Art Unit: 1638

under item 11. Applicants traverse in the paper submitted July 15, 2003. Applicants' arguments have been fully considered but were not found persuasive.

Applicants argue that since it was not known prior to the instant invention that the *dzr1* gene product negatively regulated the 10 kDa zein, *via* its 3' UTR, there could be not motivation or suggestion to combine the cited prior art references to produce the presently claimed invention, drawn to a method to solve the problem of negative regulation of the 10 kDa zein, which also comprises expressing the 10 kDa zein regardless of the *dzr1* allelic composition of the seeds (response, page 15, 1st full paragraph).

However, first, it is noted that if the host corn plant does not have a *dzr1* allele, then there is no problem of negative regulation of the 10 kDa zein to be solved. Further, the motivation to do what Applicants have done does not have to be the same as the Applicants' to reach a conclusion of obviousness. "It is sufficient if the prior art clearly suggests doing what [applicants] have done, although the underlying explanation of exactly why this should be done, other than to obtain the expected superior beneficial results, is not taught or suggested in the cited references." *In re Gershon*, 372 F.2d 535, 539, 152 USPQ 602, 605 (CCPA 1967). The prior art teaches the production of transgenic corn plants in which the 10 kDa delta zein is overexpressed, including in seeds, wherein the transgenic material comprises the coding region of a maize 10 kDa delta zein operably linked to a promoter and a heterologous 3' UTR, as does the claimed invention. Applicants are of the opinion that the claimed invention is unobvious because it wasn't known that dzr1 negatively regulates the 10 kDa zein through its 3' UTR. However, the reason for replacing the 3' UTR in the prior art does not have to be the same as that of the Applicants. The instant claims indicate that it does not matter what the *dzr1* allele

Art Unit: 1638

composition of the corn plant is. Therefore, this recitation does not limit any prior art host corn plant. The prior art also does not limit the *dzr1* allelic composition of the host corn plant to be transformed. It also would have been obvious to cross the transgenic corn plants with other corn plants, for the purpose of producing further generations of plants that comprise the chimeric gene and whose seeds produce an increased amount of methionine.

Claims 11, 13, 14, 17 remain and claims 22-27, 29, and 30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kirihara et al. (Mol. Gen. Genet., 1988, Vol. 211, pages 477-484) in combination with Russell et al. (Trans. Res., Vol. 6, 1997, pages 157-168), and Hirt et al. (Curr. Genet., Vol. 17, 1990, pages 473-479), for the reasons of record stated in the Office action mailed January 16, 2003 under item 12. Applicants traverse in the paper submitted July 15, 2003. Applicants' arguments have been fully considered but were not found persuasive.

Applicants present the same argument as for the rejection above. Applicants' argument is not found persuasive, for the reasons discussed above.

Summary

- 14. Claims 11, 13, 14, 16, and 17 remain and claims 22-27, 29, and 30 are rejected. Claim 28 is objected.
- 15. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Art Unit: 1638

final action.

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this

Contact Information

Any inquiry concerning this or earlier communications from the examiner should be directed to Ashwin Mehta, whose telephone number is 703-306-4540. The examiner can normally be reached on Mondays-Thursdays and alternate Fridays from 8:00 A.M to 5:30 P.M. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson, can be reached at 703-306-3218. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 and 703-872-9306 for regular communications and 703-872-9307 for After Final communications. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

October 28, 2003

Ashwin D. Mehta, Ph.D. Primary Examiner
Art Unit 1638

A Med